New drug shows promise for painful skin condition
NCT ID NCT04762277
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether spesolimab, an anti-inflammatory drug, can reduce painful lumps and abscesses in adults with moderate to severe hidradenitis suppurativa. Fifty-two participants were randomly assigned to receive either spesolimab or a placebo for about 3 months. Doctors counted skin lesions to compare results between the groups. The trial has completed, and results may help determine if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- spesolimab
- What this could lead to
- If it works, this could point toward a new treatment option for people with hidradenitis suppurativa who don't respond to current therapies.
- What could go wrong
- This is a small, early-phase trial with only 52 participants. The drug may not prove more effective than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Universitaria Pisana
Pisa, 56126, Italy
-
CLI Reims Bezannes
Bezannes, 51430, France
-
Cityclinic Medical and Psychological Clinic Matusiak Partnership
Wroclaw, 50-566, Poland
-
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250, United States
-
Dermatology Research Associates
Los Angeles, California, 90045, United States
-
Dr. S. K. Siddha Medicine Professional Corporation
Newmarket, Ontario, L3Y 5G8, Canada
-
Erasmus Medisch Centrum
Rotterdam, 3015 GD, Netherlands
-
HOP Edouard Herriot
Lyon, 69003, France
-
HOP Larrey
Toulouse, 31059, France
-
Haukeland Universitetssykehus
Bergen, N-5021, Norway
-
Holdsworth House Medical Practice
Sydney, New South Wales, 2010, Australia
-
Hospital Santa Creu i Sant Pau
Barcelona, 08026, Spain
-
Katholisches Klinikum Bochum gGmbH
Bochum, 44791, Germany
-
Mayo Clinic, Rochester
Rochester, Minnesota, 55905, United States
-
Non-Public Health Care Facility LABDERM
Ossy, 42624, Poland
-
Nordlandssykehuset HF, Bodø
Bodø, 8005, Norway
-
Oslo Universitetssykehus HF, Rikshospitalet
Oslo, N-0372, Norway
-
Ospedali Riuniti di Ancona
Ancona, 60123, Italy
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
Städtisches Klinikum Dessau
Dessau, 06847, Germany
-
ULB Hopital Erasme
Brussels, 1070, Belgium
-
Unity Clinical Research
Oklahoma City, Oklahoma, 73118, United States
-
University Hospital Ostrava
Ostrava, 708 52, Czechia
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60596, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Head-to-Head: which pill tames hidradenitis suppurativa best?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could early treatment tame a painful skin condition?
- New pill shows promise for controlling painful skin condition in long-term trial
- New shot could ease painful skin condition
- New pill for painful skin disease enters first human tests